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Abstract
Background: The FDA recently moved loratadine (Claritin) from prescription only status to
over-the-counter (OTC). In response to the availability of an OTC non-sedating antihistamine,
many managed care organizations are reevaluating which if any prescription antihistamines should
remain on formulary. From a managed care perspective, determining which of the remaining
prescription antihistamines results in the greatest patient satisfaction with allergy treatment would
be informative.
Methods: We report on a weighted cross sectional survey (n = 10,023) delivered online to a
sample of allergy sufferers in the U.S. during the month of December 2002. Two segments were
identified for analysis: patient who were dissatisfied with loratadine and converted to desloratadine
(Clarinex; n = 61), and patients who were dissatisfied with loratadine and converted to
fexofenadine (Allegra; n = 211). The two segments were compared along a series of measures that
the literature suggests are related to treatment satisfaction.
Results: The survey found that two of the satisfaction measures differentiated desloratadine
converters from fexofenadine converters (p < .05): mean sum of self-reported adverse events and
nighttime awakening due to allergy symptoms. For the remainder of satisfaction measures though,
patients who were dissatisfied with loratadine reported equal duration of coverage and satisfaction
with desloratadine as fexofenadine. When severity of disease was controlled for in the analysis, a
pattern emerged suggesting greater levels of satisfaction amongst loratadine dissatisfied patients
who converted to desloratadine. Point estimates suggest a consistent pattern favoring
desloratadine patient satisfaction, with statistically significant results reported for sum of adverse
effects, nighttime awakening due to symptoms, symptom severity just prior to the next dose, and
overall satisfaction (p < 0.05).
Conclusions: On average, patients who were dissatisfied with loratadine reported equal or better
satisfaction with desloratadine as fexofenadine. Patients with severe allergic rhinitis reported
greater satisfaction when converted from loratadine to desloratadine than fexofenadine for select
satisfaction measures. These results suggest that if managed care intends to position prescription
antihistamines as second line for OTC loratadine treatment dissatisfaction, desloratadine is a useful
treatment alternative. These findings, while informative to formulary decision-makers, must be
interpreted with caution. Only through head-to-head controlled clinical trials can differences in
efficacy and safety be established.
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Background
The FDA recently allowed loratadine (Claritin) to move
from prescription only status to over-the-counter (OTC).
Given the high prevalence of allergic rhinitis in the popu-
lation, this move has wide-ranging implications for both
patients who are regular prescription allergy medication
users as well as allergy sufferers who already rely on OTC
products to treat their allergies. As of December, 2002
15% of the U.S. prescription antihistamine market was
allocated to loratadine use [1]. These patients are now
faced with the option of OTC loratadine or a transition to
another prescription antihistamine. For existing OTC
users, a non-sedating antihistamine is now available with-
out a doctor's prescription, thus increasing the conven-
ience and availability of safe and effective allergy
medications.
In response to the availability of an OTC non-sedating
antihistamine, many managed care organizations are
reevaluating which if any prescription antihistamines
should remain on formulary. These decisions reflect, in
part, a movement of brand-name antihistamines to tier
three status on many formularies [2–4]. Prescription
allergy medications such as fexofenadine (Allegra),
desloratadine (Clarinex), and cetirizine (Zyrtec) (which
represent over 75% of the U.S. prescription antihistamine
market),[1] are increasingly being placed on the third tier
of managed care drug benefit plans which requires the
largest co-pay from patients. Patient co-payments at this
benefit level can range from $30 to $50 dollars [2,4], ren-
dering prescription antihistamine treatment an expensive
option for allergy sufferers. From a managed care perspec-
tive, shifting a greater proportion of the direct cost of
allergy care to the patient can act as an incentive for
patients to consider over-the-counter loratadine as first
line therapy. Managed care's role in allergy treatment may
therefore become more focused on providing treatment
alternatives to those patients who do not find adequate
symptom relief from loratadine. Therefore, determining
which of the currently available prescription antihista-
mines results in the greatest patient satisfaction with
allergy treatment (given dissatisfaction with loratadine
treatment) would be informative as managed care formu-
lary decision makers and benefit plan designers attempt to
maximize enrollee health and satisfaction at the lowest
cost.
To better understand patient satisfaction with available
prescription antihistamines, this research examined satis-
faction outcomes between patients who reported dissatis-
faction with loratadine and switched to desloratadine,
and patients who reported dissatisfaction with loratadine
and switched to fexofenadine. Cetirizine (Zyrtec) was
excluded from these analyses because its label reports an
increased incidence of sedation. There is a body of litera-
ture to suggest that untreated or under-treated allergic
rhinitis is also associated with fatigue and sedation [14].
As a result, Zyrtec was excluded from the analysis because
perceived efficacy is related to cognitive functioning and
we assume that perceived efficacy is a dimension of
patient satisfaction.
By focusing on patients who self-reported switching anti-
histamines due to dissatisfaction with loratadine treat-
ment, the results of this study would be directly applicable
to the patient population that managed care will poten-
tially need to provide alternative allergy treatment options
(e.g., prescription antihistamine, nasal steroids, immuno-
therapy). Additionally, we examine satisfaction outcomes
between these patient segments for self-reported severe
allergy sufferers, thus allowing us to explore the differen-
tial satisfaction outcomes within the patient population
in most need of effective allergy treatment.
Methods
Study Sample
The results of this paper are drawn from a larger study,
reflecting a nationally representative sample of U.S.
allergy sufferers (n = 10,023) conducted online during the
month of December, 2002. Data were weighted to reflect
demographics of the U.S. adult population which suffers
from seasonal or perennial allergies. Weighting targets
were based on the results of the December, 2002 Harris
Poll®, a telephone poll that randomly surveyed over 1,000
U.S. adults. All U.S. resident allergy sufferers over the age
of 18 were included in the weighting. They were weighted
by educational attainment, age by sex, race/ethnicity,
region, and household income to be representative of the
population of adult allergy sufferers in the U.S. This larger
study design included over 18 patient segments, reflecting
specific treatment practices, disease states, current medica-
tions, and medication switching behavior.
From this larger study, two patient segments were identi-
fied for analysis within this paper: patients who were dis-
satisfied with loratadine and converted to desloratadine
(Clarinex; n = 61), and patients who were dissatisfied with
loratadine and converted to fexofenadine (Allegra; n =
211). Qualification was determined in the screener sec-
tion of the survey. In order to qualify for these segments,
patients had to meet certain criteria. They had to have
been on each medication (previous and current) for at
least one week, with no more than one year elapsed
between product usages, and the patient reported that the
reason for switching products was dissatisfaction with
loratadine. Patients who reported combination prescrip-
tion product use did not qualify for these segments (e.g.,
prescription antihistamine use and prescription nasal ster-
oid use). However, patients who reported concomitant
OTC use were allowed in these segments. Once identifiedBMC Family Practice 2003, 4 http://www.biomedcentral.com/1471-2296/4/10
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for qualification, patients completed survey questions
which examined disease state and medication behavior,
reasons for switching products, and satisfaction with pre-
vious and current medications.
Study Measures
The two segments were compared along a series of meas-
ures that the literature suggests are related to treatment
satisfaction [5–7]. We asked patients to assess their prod-
uct satisfaction across three categories: side effects associ-
ated with the medication, satisfaction with symptom
relief, and overall satisfaction. For side effects, patients
identified instances of adverse events or side effects asso-
ciated with each medication experience. The list of side
effects included the following: difficulty falling asleep,
trouble sleeping through the night, trouble waking up,
early wakening, daytime drowsiness, nervousness, mood
swings, poor concentration, reduced ability to be produc-
tive at work/school, headache, nausea, fatigue, dry mouth,
and other. For each respondent, we summed the recorded
instances of medication-related side effects or adverse
events and created a composite measure, reported as "sum
of adverse events." All analyses examined mean differ-
ences in this measure between the two patient segments.
For satisfaction related to symptom relief, we asked
respondents to assess their medication in five ways.
Respondents were asked to indicate how effective their
medication was in covering their symptoms through to
the next dose, a measure we report as "coverage period."
This measure is based on a seven point Likert scale, where
1 equals not effectively at all and 7 equals extremely effec-
tively. Additionally, respondents were asked to indicate
how quickly their medication begins to relieve their symp-
toms after they dose, a measure we report as "onset of
relief." This measure is based on a seven point Likert scale,
where 1 equals not quickly at all and 7 equals extremely
quickly. Respondents were also asked to indicate how fre-
quently their allergy symptoms prevented them from
sleeping through the night, a measure we report as "end of
dose failure – nighttime awakenings." This measure is
based on a seven point Likert scale, where 1 equals not fre-
quently at all and 7 equals extremely frequently. Respond-
ents were further asked to indicate how troubled they
were by their allergy symptoms when they get out of bed
in the morning, a measure we report as "end of dose fail-
ure – morning symptoms." This measure is based on a
seven point Likert scale, where 1 equals not troubled at all
and 7 equals extremely troubled. And finally, respondents
were asked to indicate their overall level of symptom relief
they attained while taking their prescription medication,
a measure we report as "overall symptom relief." This
measure is based on a seven point Likert scale, where 1
equals no relief and 7 equals complete relief.
For overall prescription medication satisfaction, we asked
respondents to indicate product satisfaction in four ways.
Respondents were asked to indicate how likely they were
to recommend their current prescription medication to a
friend or family member, a measure we report as "likeli-
hood to recommend." This measure is based on a seven
point Likert scale, where 1 equals not likely at all and 7
equals extremely likely. Additionally, respondents were
asked to indicate how likely they were to continue their
current prescription medication, a measure we report as
"continuation intentions." This measure is based on a
seven point Likert scale, where 1 equals not likely at all
and 7 equals extremely likely. Respondents were also
asked to indicate their overall satisfaction with their cur-
rent prescription medication, a measure we report as
"overall satisfaction with current Rx." This measure is
based on a seven point Likert scale, where 1 equals
extremely unsatisfied and 7 equals extremely satisfied.
And finally, respondents were asked to indicate their over-
all satisfaction with the change in prescription products, a
measure we report as "satisfaction with Rx switch." This
measure is based on a seven point Likert scale, where 1
equals extremely unsatisfied and 7 equals extremely satis-
fied. For a summary of the satisfaction Likert scales used
in this analysis, see table 1.
The two patient segments were compared along the above
listed satisfaction measures as complete segments and
separately as severe sufferers within the two segments.
Severity of disease was assessed on a self-reporting basis of
how troubled the patient was by his or her allergies.
Severe sufferers were identified by responses of quite a bit
troubled, very troubled, or extremely troubled on a seven
point Likert scale (top three box). For the severity sub-
group analyses, the weighted segments sizes were 88 for
loratadine-fexofenadine and 35 for loratadine-deslorata-
dine.
To test for mean differences in the ten separate study
measures, difference in means tests were conducted using
the t-distribution. All significance testing was performed
at the 95% confidence level, two-tailed.
Although respondents were asked to assess their prescrip-
tion medication across categories related to perceived effi-
cacy and side effects, an important caveat to highlight is
the fact that patient perceptions regarding medication use
captured through survey research cannot establish differ-
ences in the clinical properties related to efficacy or safety.
The survey research reported here was designed to assess
dimensions of satisfaction, across patient self-reported
categories of side effects, efficacy, and overall product sat-
isfaction. Only through head-to-head controlled clinical
trials can differences in efficacy and safety be established.BMC Family Practice 2003, 4 http://www.biomedcentral.com/1471-2296/4/10
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Table 1: 
Dimensions of Patient Satisfaction – Semantic Differential Likert Scales
Negative Endpoint 1 Positive Endpoint 7
Symptom Relief
EOD Failure – Nighttime Awakening Not Frequently at All Extremely Frequently
EOD Failure – Morning Symptoms Not Troubled at All Extremely Troubled
Onset of Relief Not Quickly at All Extremely Quickly
Coverage Period Not Effectively at All Extremely Effectively
Overall Symptom Relief No Relief Complete Relief
Overall Satisfaction
Continuation Intentions Extremely Unlikely Extremely Likely
Likelihood to Recommend Extremely Unlikely Extremely Likely
Overall Satisfaction with Current Rx Extremely Unsatisfied Extremely Satisfied
Satisfaction with Rx Change Extremely Unsatisfied Extremely Satisfied
Table 2: 
Loratadine Dissatisfied Segments
Converted to Fexofenadine N = 211 
(weighted)
Converted to Desloratadine N = 61 (weighted)
Side Effects
Sum of Adverse Events1 1.59* 1.32*
Symptom Relief
EOD Failure – Nighttime Awakening1 2.26* 1.85*
EOD Failure – Morning Symptoms1 3.33 3.12
Onset of Relief2 4.56 4.72
Coverage Period2 4.84 5.02
Overall Symptom Relief2 5.30 5.35
Overall Satisfaction
Continuation Intentions2 5.39 5.44
Likelihood to Recommend2 5.06 5.38
Overall Satisfaction with Current Rx2 5.13 5.28
Satisfaction with Rx Change2 5.17 5.32
*p < = .05 **p < = .01 1 Higher number reflects negative medication experience. 2 Higher number reflects positive medication experience.
Table 3: 
Loratadine Dissatisfied Segments – Severe Allergic Rhinitis
Converted to Fexofenadine N = 88 (weighted) Converted to Desloratadine N = 35 (weighted)
Side Effects
Sum of Adverse Events1 2.0** 1.35**
Symptom Relief
EOD Failure – Nighttime Awakening1 2.93** 1.81**
EOD Failure – Morning Symptoms1 3.74 3.62
Onset of Relief2 4.34 4.58
Coverage Period2 4.37** 5.15**
Overall Symptom Relief2 4.92 5.34
Overall Satisfaction
Continuation Intentions2 5.10 5.41
Likelihood to Recommend2 4.66 5.32
Overall Satisfaction with Current Rx2 4.67* 5.37*
Satisfaction with Rx Change2 4.76 5.27
*p < = .05 **p < = .01 1 Higher number reflects negative medication experience. 2 Higher number reflects positive medication experience.BMC Family Practice 2003, 4 http://www.biomedcentral.com/1471-2296/4/10
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Results
Full Segments
When examining the full segments, the survey found that
two of the satisfaction measures differentiated deslorata-
dine converters from fexofenadine converters (p < .05):
mean sum of adverse events and end of dose failure –
nighttime awakenings. Patients who switched to deslorat-
adine experienced significantly less instances of medica-
tion-related adverse events, when compared with patients
who switched to fexofenadine (see table 2). Additionally,
loratadine-desloratadine patients reported significantly
less frequent nighttime awakenings due to allergy symp-
toms (see table 2). As this measure gauges the medica-
tion's coverage period of symptom relief, this differential
outcome speaks to the greater satisfaction associated with
the buffering of end of dose failure symptoms for
desloratadine when compared with fexofenadine.
For the remainder of the satisfaction measures, patients
who were dissatisfied with loratadine and switched to
desloratadine reported equal outcomes when compared
with patients who switched to fexofenadine. However, as
table 2 shows, point estimates for these satisfaction meas-
ures reveal a consistent pattern favoring desloratadine
outcomes, although differences were not found to be sta-
tistically significant. In short, for these measures, the data
clearly suggest that fexofenadine does not offer a better
satisfaction outcome for patients who are dissatisfied with
loratadine, when compared with desloratadine.
Severe Allergy Sufferer Segments
When severe allergy sufferers were analyzed separately, a
pattern emerged suggesting greater levels of satisfaction
amongst loratadine dissatisfied patients who converted to
desloratadine when compared with loratadine dissatisfied
patients who converted to fexofenadine. Point estimates
again suggest a consistent pattern favoring desloratadine
patient satisfaction, with statistically significant results
reported for sum of adverse events, end of dose failure –
nighttime awakenings, end of dose failure – morning
symptoms, and overall satisfaction with current Rx (p <
0.05). As with the full segments, severe allergy sufferers
who switched from loratadine to desloratadine due to dis-
satisfaction reported significantly less instances of medi-
cation-related adverse events, when compared with
similar patients who switched to fexofenadine (see table
3). For the two end of dose failure satisfaction measures,
loratadine-desloratadine patients reported significantly
less frequent nighttime awakenings due to allergy symp-
toms as well as being significantly less troubled by their
allergy symptoms upon morning awakening (see table 3).
For overall satisfaction, severe loratadine-desloratadine
patients reported significantly greater levels of satisfaction
with their current antihistamine when compared with
severe loratadine patients who switched to fexofenadine.
In total, when the satisfaction-related categories of
reported medication side effects, assessments of symptom
relief, and reports of overall satisfaction were considered,
severe patients who had switched to desloratadine
reported increased satisfaction when compared with
severe patients who switched to fexofenadine.
Discussion
The results of this study show that for patients who report
dissatisfaction with loratadine, a product switch to
desloratadine offers equal, and in many instances,
increased benefits along a series of product-related satis-
faction measures when compared to a switch to fexofena-
dine. When all patients were considered, the most striking
finding involved the significantly reduced frequency of
nighttime awakenings due to allergy symptoms for
desloratadine outcomes. As previous research has docu-
mented the importance of sleeping through the night for
allergy sufferers [8], this finding speaks to a crucial com-
ponent of product satisfaction favoring desloratadine
conversion. Indeed, when severe sufferers were examined
separately, both satisfaction measures related to end of
dose failure favored desloratadine outcomes. Severe suf-
ferers are arguably more likely to be awakened in the mid-
dle of the night due their severe symptoms as well as being
more likely to report severe symptoms upon awakening
[9–14]. As a result, an antihistamine which correlates with
greater satisfaction along these coverage period dimen-
sions would be valued by the severe allergy sufferer. To
that end, the results of this survey suggest that deslorata-
dine offers that benefit, when compared with fexofena-
dine (for severe allergy sufferers who failed on
loratadine). This finding supports other research that
highlights the 24 hour coverage associated with deslorat-
adine [15,16])
The survey findings also reveal that severe sufferers who
were dissatisfied with loratadine and switch to deslorata-
dine report greater levels of satisfaction when compared
with patients who switch to fexofenadine. This global
assessment of satisfaction speaks favorably to the overall
outcomes of desloratadine conversion, when specifically
targeting patients who suffer from severe allergy symp-
toms. As severe allergy sufferers have the most to gain
from allergy medication, this finding positions deslorata-
dine as a beneficial treatment approach for severe sufferers
who gain little satisfaction from loratadine use.
Limitations
One limitation of this study is that it only focuses on two
product switching pathways. Although loratadine, fex-
ofenadine, and desloratadine represented close to two-
thirds of the U.S. antihistamine market at the time of the
survey fielding, knowledge about patients who are dissat-
isfied with loratadine and switch to cetirizine is unknownPublish with BioMed Central    and   every 
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at this time. Understanding this specific switching path-
way represents fruitful grounds for future research.
Another study limitation involves the interpretation of
data associated with product switchers. It must be
acknowledged that inferences from these data can only be
applied to a specific sub-segment of the antihistamine
market, namely those allergy patients who were dissatis-
fied with loratadine and converted to either fexofenadine
or desloratadine. Interpretations beyond this population
would be suggestive in nature, and should be approached
with caution.
Conclusions
On average, patients who were dissatisfied with loratadine
reported equal or better satisfaction with desloratadine as
fexofenadine. Patients with severe allergic rhinitis
reported greater satisfaction when converted from lorata-
dine to desloratadine than fexofenadine for select satisfac-
tion measures. These results suggest that if managed care
intends to position prescription antihistamines as second
line for patients who are not satisfied with OTC lorata-
dine, desloratadine is a useful treatment alternative. These
findings, while informative to formulary decision-makers,
must be interpreted with caution. Only through head-to-
head controlled clinical trials can differences in efficacy
and safety be established.
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